FBInvestor
Funds / Tcg Crossover Management, LLC
Institutional Fund

Tcg Crossover Management, LLC

Palo Alto, CACIK 18399485 filings on record

Portfolio Value
$3.50B
Q1 2026
Holdings
49
Reported positions
New Buys
11
Opened this quarter
QoQ Change
+15.7%
from $3.02B

Portfolio Value Trend

Reported 13F value by quarter

Portfolio value trend — upgrade to see history

Upgrade

Top Allocations

Largest positions by weight

  • Abivax SA20.6%
  • Cg Oncology Inc7.1%
  • Tango Therapeutics Inc6.3%
  • Cogent Biosciences Inc5.4%
  • Centessa Pharmaceuticals PLC4.9%
  • Dianthus Therapeutics Inc4.0%
  • Other51.6%

Portfolio Holdings

49 positions · Q1 2026

#SecuritySharesValue% Port.Δ SharesActivity
1Abivax SA6.48M$721.67M20.6%630.5KReduced
2Cg Oncology Inc3.67M$248.40M7.1%0Held
3Tango Therapeutics Inc10.53M$220.31M6.3%2.23MReduced
4Cogent Biosciences Inc4.95M$190.41M5.4%921.3KReduced
5Centessa Pharmaceuticals PLC4.29M$170.26M4.9%0Held
6Dianthus Therapeutics Inc1.68M$140.70M4.0%0Held
7Tyra Biosciences Inc3.25M$124.44M3.6%+350.9KAdded
8Immunovant Inc4.46M$110.74M3.2%+2.80MAdded
9Biocryst Pharmaceuticals Inc11.02M$104.92M3.0%+11.02MNew
10Mirum Pharmaceuticals Inc1.06M$98.11M2.8%+1.00MAdded

39 more holdings on Premium

See this fund's complete portfolio, full position changes, and activity history.

Unlock full portfolio